Published in Proc Natl Acad Sci U S A on May 01, 2012
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62
Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res (2014) 1.63
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 1.43
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med (2014) 1.38
Targeting hedgehog signaling in cancer: research and clinical developments. Onco Targets Ther (2013) 0.99
Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res (2015) 0.96
Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups. Proc Natl Acad Sci U S A (2013) 0.95
Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. J Neurooncol (2012) 0.93
The rationale for targeted therapies in medulloblastoma. Neuro Oncol (2013) 0.92
Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. Expert Rev Mol Med (2015) 0.87
RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. Cancer Res (2015) 0.87
Advanced treatment for basal cell carcinomas. Cold Spring Harb Perspect Med (2014) 0.86
Pediatric medulloblastoma - update on molecular classification driving targeted therapies. Front Oncol (2014) 0.85
Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunol Res (2015) 0.84
Efficacy of cabazitaxel in mouse models of pediatric brain tumors. Neuro Oncol (2014) 0.84
Targeted treatment for sonic hedgehog-dependent medulloblastoma. Neuro Oncol (2014) 0.83
In vivo Mn-enhanced MRI for early tumor detection and growth rate analysis in a mouse medulloblastoma model. Neoplasia (2014) 0.82
RNA binding protein-mediated post-transcriptional gene regulation in medulloblastoma. Mol Cells (2014) 0.82
Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget (2016) 0.81
Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. Bioorg Med Chem (2012) 0.79
NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. Pharmacol Res Perspect (2014) 0.78
Medulloblastoma development: tumor biology informs treatment decisions. CNS Oncol (2015) 0.78
Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics. Curr Med Chem (2015) 0.77
The Role of Hedgehog Signaling in Tumor Induced Bone Disease. Cancers (Basel) (2015) 0.77
Targeting the Hedgehog Pathway in Pediatric Medulloblastoma. Cancers (Basel) (2015) 0.76
Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype. Cell Death Dis (2016) 0.76
MicroRNA Biogenesis and Hedgehog-Patched Signaling Cooperate to Regulate an Important Developmental Transition in Granule Cell Development. Genetics (2016) 0.76
Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma. J Exp Pharmacol (2012) 0.75
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature (2000) 10.04
Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev (2002) 8.56
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell (2004) 5.95
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell (2008) 5.06
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med (2009) 2.95
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res (2009) 1.77
Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res (2011) 1.72
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem (2009) 1.58
Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res (2006) 1.56
Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res (2008) 1.30
Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines. Mol Cancer Res (2010) 0.96
International network of cancer genome projects. Nature (2010) 20.35
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Follicular lymphoma international prognostic index. Blood (2004) 7.20
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell (2008) 5.06
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood (2002) 4.06
Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet (2006) 3.91
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 3.56
The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res (2004) 3.33
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol (2012) 3.01
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer (2005) 2.91
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Pancreatic beta-cell failure and diabetes in mice with a deletion mutation of the endoplasmic reticulum molecular chaperone gene P58IPK. Diabetes (2005) 2.46
Imputation methods to improve inference in SNP association studies. Genet Epidemiol (2006) 2.41
New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol (2005) 2.40
Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res (2009) 2.28
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther (2008) 2.21
The completion of the Mammalian Gene Collection (MGC). Genome Res (2009) 2.21
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet (2002) 2.17
Regulation of thalamocortical patterning and synaptic maturation by NeuroD2. Neuron (2006) 2.15
In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small (2008) 2.09
Risk prediction using genome-wide association studies. Genet Epidemiol (2010) 2.03
Nonpuerperal uterine inversion associated with an immature teratoma of the uterus in an adolescent. Obstet Gynecol (2007) 2.02
Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry (2004) 1.89
Rab23, a negative regulator of hedgehog signaling, localizes to the plasma membrane and the endocytic pathway. Traffic (2003) 1.88
The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res (2008) 1.84
Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria. J Gerontol A Biol Sci Med Sci (2008) 1.83
Significance testing for small microarray experiments. Stat Med (2005) 1.80
Design of highly emissive polymer dot bioconjugates for in vivo tumor targeting. Angew Chem Int Ed Engl (2011) 1.76
Massively parallel polymerase cloning and genome sequencing of single cells using nanoliter microwells. Nat Biotechnol (2013) 1.69
Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci (2005) 1.68
BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med (2003) 1.67
Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci (2007) 1.66
Frontal lobe gray matter density decreases in bipolar I disorder. Biol Psychiatry (2004) 1.65
N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res (2006) 1.64
Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord (2006) 1.59
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem (2009) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol (2008) 1.56
Novel small-molecule inhibitors of RNA polymerase III. Eukaryot Cell (2003) 1.56
The SEQanswers wiki: a wiki database of tools for high-throughput sequencing analysis. Nucleic Acids Res (2011) 1.56
Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res (Phila) (2010) 1.55
Craniosynostosis: imaging review and primer on computed tomography. Pediatr Radiol (2013) 1.54
Novel genes regulated by Sonic Hedgehog in pluripotent mesenchymal cells. Oncogene (2002) 1.51
Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet (2005) 1.51
Genetic control of the innate immune response. BMC Immunol (2003) 1.50
Proton magnetic resonance spectroscopy and MRI reveal no evidence for brain mitochondrial dysfunction in children with autism spectrum disorder. J Autism Dev Disord (2012) 1.49
PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol (2013) 1.47
Conservation of regional gene expression in mouse and human brain. PLoS Genet (2007) 1.47
Tracing conidial fate and measuring host cell antifungal activity using a reporter of microbial viability in the lung. Cell Rep (2012) 1.45
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet (2002) 1.45
A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. Hum Mol Genet (2002) 1.43
Neuroimaging of mitochondrial disease. Mitochondrion (2008) 1.43
PEI-PEG-Chitosan Copolymer Coated Iron Oxide Nanoparticles for Safe Gene Delivery: synthesis, complexation, and transfection. Adv Funct Mater (2009) 1.42
Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet (2005) 1.42
Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet (2002) 1.41
Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet (2005) 1.39
Facilitating genome navigation: survey sequencing and dense radiation-hybrid gene mapping. Nat Rev Genet (2005) 1.33
Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet (2002) 1.33
Amygdalar volume and behavioral development in autism. Arch Gen Psychiatry (2006) 1.32
Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev (2013) 1.31
Generation of diversity in the innate immune system: macrophage heterogeneity arises from gene-autonomous transcriptional probability of individual inducible genes. J Immunol (2002) 1.28
Kif7 regulates Gli2 through Sufu-dependent and -independent functions during skin development and tumorigenesis. Development (2012) 1.28
Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed (2009) 1.26
DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci U S A (2009) 1.26
Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data. BMC Bioinformatics (2006) 1.24
Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. Mol Cancer (2007) 1.24
Interim futility analysis with intermediate endpoints. Clin Trials (2008) 1.23
Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (Lond) (2008) 1.22
Semiparametric estimation exploiting covariate independence in two-phase randomized trials. Biometrics (2008) 1.21
MyD88 signaling contributes to early pulmonary responses to Aspergillus fumigatus. Infect Immun (2007) 1.20
The dosage of the neuroD2 transcription factor regulates amygdala development and emotional learning. Proc Natl Acad Sci U S A (2005) 1.19
A class of models for analyzing GeneChip gene expression analysis array data. BMC Genomics (2005) 1.18
Assessing bias in experiment design for large scale mass spectrometry-based quantitative proteomics. Mol Cell Proteomics (2007) 1.18
Wnt2 coordinates the commitment of mesoderm to hematopoietic, endothelial, and cardiac lineages in embryoid bodies. J Biol Chem (2006) 1.18
Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol (2012) 1.17
Tissue inhibitor of metalloproteinase-1 deficiency amplifies acute lung injury in bleomycin-exposed mice. Am J Respir Cell Mol Biol (2005) 1.17
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2012) 1.17
Chimeric constructs endow the human CFTR Cl- channel with the gating behavior of murine CFTR. Proc Natl Acad Sci U S A (2007) 1.17
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer (2012) 1.16
Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. J Infect Dis (2013) 1.15